We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low-Cost Point-of-Care Test Monitors HIV Treatment

By LabMedica International staff writers
Posted on 03 Jun 2009
Scientists developed a prototype low-cost HIV monitoring test designed for field use in remote settings.

Developed by Australian scientists, the new test enables patients at the point of care to find out within 30 minutes if they should begin antiretroviral treatment, without any laboratory equipment being required.

The Burnet Institute (Melbourne, Australia) was awarded a grant by The CD4 Initiative for the development of a low cost, rapid point-of-care CD4+ T-cell test, specifically designed for field use in remote settings. More...
Professor Suzanne Crowe, Associate Professor David Anderson, and senior scientist Mary Garcia lead the team at Burnet, which has expertise in diagnostic test development.

The CD4 rapid test, similar in design to a home pregnancy test, works with a finger-prick blood sample to measure the numbers of CD4+ T-cells in a person's blood. CD4+ T-cells are critical for healthy functioning of the immune system and are slowly destroyed during the course of HIV infection. When the numbers of CD4+ T-cells in a person's blood decrease to a critical level, they become increasingly vulnerable to illness. Healthcare workers rely on a CD4 count when making decisions about when HIV-positive patients should begin antiretroviral therapy.

The majority of patients in the developing world do not currently have access to CD4 testing because it is expensive, and relies on sophisticated laboratory testing and specially trained operators. Where testing facilities exist, it is often too difficult for people in rural areas to access them and it can take weeks to obtain results.

Having completed the first phase of trials, the prototype test developed by the Burnet Institute scientists will undergo further validation and clinical studies to ensure the assay offers reliable and reproducible results.

Related Links:

Burnet Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.